Genetic and Epigenetic Characterization of Colorectal and Endometrial Cancer by Kuismanen, Shannon
 
Genetic and Epigenetic Characterization of 
Colorectal and  
Endometrial Cancer 
 
 
 
 
 
 
 
Shannon A. Kuismanen 
 
 
 
 
 
 
 
Department of Medical Genetics 
Biomedicum 
University of Helsinki 
Finland 
 
 
 
 
 
 
 
 
 
To be publicly discussed, with the permission of the Medical Faculty of 
the University of Helsinki, in the lecture hall 2, Biomedicum Helsinki, 
Haartmaninkatu 8, on 9 June 2006, at 12 noon. 
 2
 
Supervised by: 
 
Professor Päivi Peltomäki, MD, PhD 
Department of Medical Genetics 
University of Helsinki 
Helsinki, Finland 
 
 
Reviewed by: 
 
Maija Wessman, PhD, Doc 
Academy Research Fellow 
Folkhälsän Research Center and  
Finnish Genome Center 
Helsinki University Hospital 
Helsinki, Finland 
 
Ari Ristimäki, MD, PhD, Doc 
Pathology/HUSLAB 
Helsinki University Central Hospital 
Molecular and Cancer Biology Research Program 
Biomedicum Helsinki 
University of Helsinki 
Helsinki, Finland 
 
 
Official opponent: 
 
Anne Kallioniemi, MD, PhD 
Professor of Cancer Genetics 
Institute of Medical Technology 
University of Tampere 
Tampere, Finland 
 
 
 
 
 
 
 
 
 
 
 
ISBN 952-92-0382-9 (paperback) 
ISBN 952-10-3169-7 (PDF) 
http://ethesis.helsinki.fi 
 
Helsinki University Press 2006 
 3
THE ROAD NOT TAKEN 
Two roads diverged in a yellow wood, 
And sorry I could not travel both 
And be one traveler, long I stood 
And looked down one as far as I could 
To where it bent in the undergrowth; 
 
Then took the other, as just as fair, 
And having perhaps the better claim, 
Because it was grassy and wanted wear; 
Though as for that the passing there 
Had worn them really about the same, 
 
And both that morning equally lay 
In leaves no step had trodden black. 
Oh, I kept the first for another day! 
Yet knowing how way leads on to way, 
I doubted if I should ever come back. 
 
I shall be telling this with a sigh 
Somewhere ages and ages hence: 
Two roads diverged in a wood, and I– 
I took the one less traveled by, 
And that has made all the difference. 
 
–  Robert Frost, 1916 
 
 
 
This thesis is dedicated to the one who took the road less traveled with me. 
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INTRODUCTION 
 
Three major types of cancer exist: sarcoma, lymphoma and leukemia, and 
carcinoma.  Sarcoma is cancer originating in the connective tissue, lymphoma 
and leukemia in the lymphatic and blood systems, and carcinoma in the 
epithelium.  All three types of cancer are considered genetic diseases.  A series of 
mistakes, called mutations, occur in the DNA of genes causing cancer to develop 
(fig. 1).  These mutations can be inherited, passed down from parent to offspring, 
or acquired during an organism’s lifetime.  An inherited mutation is found in all 
the cells of an organism, including the germline cells and the disease is 
considered heritable.  An acquired mutation only occurs in isolated somatic cells, 
and is not transmitted to the next generation.  Acquired mutations are a result of 
different internal or external factors, including, but not limited to, environmental 
pollutants, unhealthy lifestyles, and increasing longevity. 
Cancer is among the leading causes of death in the western world today, with 
colorectal cancer being one of the three most common types of cancer in both 
men and women (Finnish Cancer Registry; NAACCR).  An estimated 5-15% of 
all cancers that occur each year are accounted for by hereditary forms.  Of the 
hereditary forms of colorectal cancer, hereditary non-polyposis colorectal cancer 
(HNPCC) is the most common and accounts for an estimated 0.5-13% (Lynch 
and de la Chapelle 2003).  This is an autosomal dominant disorder and 
susceptibility is associated with germline mutations in four genes with DNA 
mismatch repair (MMR) function, a further two genes have been proposed but 
have not so far shown any clinical significance (Peltomäki 2005).  In addition to 
gastrointestinal carcinomas, HNPCC is characterized by familial accumulation of 
endometrial, gastric, urological, and ovarian tumors.  Individuals with HNPCC 
have a 70% chance of developing colon cancer during their lifetime, with 45 
being the average age of diagnosis.  In the general population, colon cancer 
occurs 20 to 30 years later and the lifetime incidence is approximately 5%.  Even 
though 75% of HNPCC cases are known to be caused by germline mutations in 
the MMR genes, the remaining cases are still molecularly unexplained.   
The objective of this work was to clarify the mechanisms that are associated 
with tumor development in HNPCC vs sporadic cases.  Of particular interest 
were the genetic events (changes in the DNA sequence) and epigenetic events 
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(changes in gene function occuring without change in the DNA sequence) that 
lead to the development of different tumors of the HNPCC tumor spectrum, 
particularly colon and endometrial cancers. 
 
 
 
 
 
 
 
Figure 1  Simplified scheme of cancer development. 
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1. REVIEW OF THE LITERATURE 
 
1.1. CANCER 
 
1.1.1. Cancer and Cancer-Associated Genes 
 
Cancer is a genetic disease in which the progression from normal 
cells to malignant ones is a multi-step process.  In cancer, cells lose their 
ability for normal, regulated cell growth and apoptosis, and without these 
regulations cells continue to grow and mutate into invasive tumors.  
Different types of genes play a role in cell regulation, including 
oncogenes, tumor suppressors, and mismatch repair genes. 
Oncogenes are modified, mutated forms of proto-oncogenes and can 
increase the chance of normal cells developing into tumor cells. Proto-
oncogenes code for proteins that regulate cell growth and differentiation.  
Tumor suppressor genes, as their name implies, lessen the chance of cells 
becoming malignant and forming tumors.  These genes code for proteins 
that typically either dampen cell cycle progression or promote apoptosis. 
Unlike oncogenes, which are activated even by a small change, tumor 
suppressor genes follow a “two-hit hypothesis” in which both alleles 
must be affected for the deactivation (Knudson 1971).  Mismatch repair 
(MMR) genes also follow this “two-hit hypothesis” and can be 
considered to be a type of tumor suppressor.  As the name suggests, these 
genes repair DNA base pair mismatches and help maintain normal base 
pair matches. 
A minor fraction of cancer, about 5% to 15%, is hereditary but the 
vast majority occurs spontaneously.  In hereditary cancer, typically one 
of the two alleles of a given gene is mutated in all cells from birth leading 
to the early onset of cancer.  In sporadic cancer, the mutations are 
acquired over time causing this form of cancer to usually occur later in 
life, through various external factors.  These factors include, but are not 
limited to, diet, environment, UV-radiation, and viral infections 
(Zuckerman 1979; Marx 1986; Marwick 1990; Graham 2000). 
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1.1.2. Colorectal Cancer 
 
Colon cancer is one of the three most common cancers (table 1a) in 
both women and men (Finnish Cancer Registry; NAACCR), with about 
148,000 new cases each year in the United States alone (American 
Cancer Society).  A majority of the cases are sporadic and are believed to 
be due to a number of previously mentioned environmental factors, 
further listed in table 1b.  Approximately 20% of the cases have a 
familial risk, though due to low penetrance of the predisposing genes this 
may be under-recognized (Lynch and de la Chapelle 2003). 
 
Table 1a  Most common cancers in men and women (% of all cancer) 
Men Women 
Prostate (33%) Breast (31%) 
Lung and bronchus (13%) Lung and bronchus (12%) 
Colon and rectum (10%) Colon and rectum (11%) 
 
 
Table 1b  Risk factors and causes of colorectal carcinoma (modified 
from Weitz et al. 2005) 
advanced age 
diabetes 
diet rich in fats, poor in fiber, folate, and calcium 
environmental factors 
high alcohol consumption  
hormonal factors 
male 
obesity 
occupational hazards (eg. asbestos exposure) 
prior irradiation 
sedentary lifestyle 
smoking 
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The progression of normal cells into metastic tumor cells is a multi-
stepped process occurring over a long period of time, usually 10-15 years 
(Vogelstein and Kinzler 1993).  Renan estimated in 1993 that a total of 
four to seven mutations, providing a clonal advantage, are needed for 
malignancy development.  This progression process is called the 
adenoma-carcinoma sequence (Fearon and Vogelstein 1990), which 
appears to be initiated by mutations in the tumor suppressor APC gene.  
This gene acts as a form of gatekeeper in colorectal cancer development.  
Additional mutations in the tumor suppressors, DCC, DPC4/Smad4, p53, 
nm32, and TGFβRII, as well as in the oncogenes, K-ras, c-myc, 
HER2/neu (erbB-2), c-src, are involved in this process.  Although 
mutations of these genes occur in a favored sequence, it is their total 
accumulation rather than chronological occurrence that determines the 
biological properties of tumors (Cho and Vogelstein 1992).   
This thesis focuses on colorectal and endometrial cancer, and listed 
in Table 2 are the most important hereditary syndromes which include 
these cancers as component tumors.  Hereditary forms of colorectal 
cancer are divided into two main classifications, polyposis and non-
polyposis syndromes.  Polyposis syndromes, as the name suggests, 
present with numerous polyps in the colon and can be further divided 
into hamartomatous (non-neoplastic indigenous tissue mass) and 
adenomatous (benign neoplastic tissue) polyposis syndromes.  Non-
polyposis syndromes do not typically have this feature. 
Harmartomatous polyposis syndromes include Peutz-Jeghers 
syndrome, juvenile polyposis syndrome, and Cowden syndrome.  
Adenomatous polyposis syndromes include familial adenomatous 
polyposis (FAP), Gardner's syndrome, part of Turcot's syndrome, 
attenuated adenomatous polyposis coli, flat adenoma syndrome, and 
MYH-associated polyposis (MAP).  Hereditary non-polyposis colorectal 
cancer represents non-polyposis syndromes.  Of hereditary colorectal 
cancer syndromes, FAP and HNPCC are the two most prevalent (Lynch 
and de la Chapelle 2003). 
Familial adenomatous polyposis affects approximately 1 in 10,000 
individuals and is an autosomal dominant disorder caused by a germline 
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mutation in the APC gene and characterized by numerous, that is 
hundreds of, polyps.  Due to the sheer number of polyps, malignant 
development is inevitable and usually occurs by the age of 35 to 40.  The 
only real treatment for this disorder is still prophylactic colectomy 
(Bisgaard et al. 1994; Galiatsatos and Foulkes 2006). 
Hereditary non-polyposis colorectal cancer sydrome is also an 
autosomal dominant disorder caused by mutations in the DNA mismatch 
repair genes.  This disorder will be discussed in more detail later. 
 
Table 2  Important hereditary syndromes with CRC and EC as component tumors.  
(Marsh and Zori 2002; Garber and Offit 2005; Jo and Chung 2005) 
 
Hereditary Syndromes Predisposing genes Tumor Spectrum
FAP APC  (AXIN2 )
CRC, papillary thyroid carcinoma, 
pancreatic adenocarcinoma, pre-
malignant duodenal polyps
MAP MYH CRC
Peutz-Jeghers syndrome STK11/LKB1 gastrointestinal, pancreas, breast, gonads, uterus, cervix
Juvenile polyposis SMAD4, BMPR1A pancreatic, stomach
Turcot Syndrome APC; PMS2, MLH1
CRC, basal cell carcinoma, 
ependymoma, medulloblastoma, 
glioblastoma
HNPCC MLH1, MSH2, MSH6, PMS2
CRC, EC, ovarian, renal pelvis, 
ureteral, pancreatic, stomach, small 
bowel, hepatobiliary
Muir-Torre syndrome MSH2 (MLH1)
CRC, sebaceous (carcinomas, 
epitheliomas, adenomas), 
keratoacanthomas, laryngeal, 
gastrointestinal, genitourinary  
Cowden syndrome PTEN
EC, breast, thyroid, skin, 
gastrointestinal tract, central nervous 
system 
Bannayan-Riley-Ruvalcaba 
syndrome PTEN
breast, meningioma, thyroid 
follicular cell tumors
m
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y 
C
R
C
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)
C
R
C
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po
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1.1.3. Endometrial Cancer 
 
Uterine cancer is the most common gynecological cancer, with 
41,000 new cases diagnosed each year in the United States alone, 
ranking it fourth for women (American Cancer Society, Surveillance 
research 2006).  Only 10% of cases are uterine sarcoma, the remaining 
cases are endometrial carcinoma.  Endometrial carcinoma (EC) can be 
further subdivided into adenocarcinoma, occuring primarily in 
perimenopausal women, and papillary serous and clear cell carcinoma, 
both occuring predominately in postmenopausal women.   
Some hereditary endometrial cancer occurs in Cowden, Turcot, 
Muir-Torre, and Bannayan-Riley-Ruvalcaba syndromes, as well as 
HNPCC (table 2).  
 
 
1.2. HEREDITARY NON-POLYPOSIS COLORECTAL CANCER (HNPCC) 
AS A CANCER MODEL 
 
1.2.1. History and Definitions 
 
The disease now known as hereditary non-polyposis colorectal 
cancer was originally described in 1913 by Aldred Scott Warthin as 
cancer family syndrome (CFS) and revisited in 1966 by Henry T. 
Lynch, giving rise to it being renamed Lynch Syndrome.   Two 
different tumor manifestation patterns emerged through research, in the 
1980s, on CFS families. In one, the tumors occurred only in the colon, 
and in the other, extracolonic tumors, particularly endometrial cancer, 
appeared. All the other characteristics, including the early onset of 
proximal colon tumors, were similar in both cases.  These observations 
led to the syndrome subsequently being referred to as two related 
syndromes, Lynch syndrome I and Lynch syndrome II.  Lynch 
syndrome I, or hereditary site-specific colon cancer (HSSCC), refers to 
the form that manifests only in the colon and Lynch syndrome II, 
previously CFS, refers to the form that manifests extracolonically, as 
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well as in the colon (Lynch et al. 1985).  Unlike other cancer 
syndromes, Lynch syndrome (I and II) presented physicians with a 
dilemma in diagnosis, due to the wide range of symptoms, as well as 
the need for a well-documented family history.  In 1991, Vasen et al. 
put forth the Amsterdam criteria as an aid for diagnosis of Lynch 
syndrome I, further modifying it in 1999 to include Lynch syndrome II 
(tables 3a and 3b).  
The term hereditary non-polyposis colorectal cancer was first 
coined in 1985 by Lynch himself; however, the work he did focused 
mainly on colon cancer and ignored the fact that many families have an 
increase in endometrial cancer occurrence as well.  Many feel that this 
name is misleading, due to its exclusion of endometrial cancer and its 
inference that there are never polyps in this syndrome.  Subsequently, a 
consensus  was reached at the last two Bethesda conferences that the 
name HNPCC is no longer the preferred one.  The name suggested 
now is Lynch Syndrome (Boland 2005; Lynch 2005).  
 
Table 3a  Amsterdam criteria I 
·three or more cases of colorectal cancer in a minimum of two 
generations
·one affected individual should be a first degree relative to the 
other cases of colorectal cancer
·one case of colorectal cancer should be diagnosed under age 50
·a diagnosis of Familial Adenomatous Polyposis (FAP) should 
be excluded  
 
Table 3b  Amsterdam criteria I 
·three or more cases of HNPCC-associated cancer (CRC, 
endometrial, small bowel, ureter, and renal pelvic) in a 
minimum of two generations
·one affected individual should be a first degree relative to the 
other cases of colorectal cancer
·one case of colorectal cancer should be diagnosed under age 50
·a diagnosis of Familial Adenomatous Polyposis (FAP) should 
be excluded  
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1.2.2. Genetic Instability 
 
Genetic instability is a succession of spontaneous genetic changes 
in cell populations, originating from the same ancestral predecessor, 
occurring at an accelerated rate.  These changes may be brought on in 
one of two ways, chromosomally (85%) or through microsatellite 
repeats (15%).  These two pathways are called the CIN, chromosomal 
instability, and the MIN, microsatellite instability, pathways.  Figure 2 
depicts the main components of each of these pathways.  Besides 
differences in the genetic components, these two pathways also 
manifest fundamental epigenetic differences: cells with CIN are 
generally methylation-deficient whereas those with MIN are 
methylation-proficient (Lengauer et al. 1997). 
Blatant chromosomal abnormalities are the signature of the CIN 
model.  These abnormalities come in the form of either gain or loss of 
chromosome material (Kinzler and Vogelstein 1996) and are typically 
associated with rapid accumulation of mutations in the tumor 
suppressor genes or oncogenes (Charames and Bapat 2003). The 
mechanisms of CIN, however, are poorly understood but, like MIN, 
may be due to defects in single genes, including those that control 
chromosome segregation (Wang et al.  2004). 
 
Chromosomal instability pathway (CIN) 
 
 
 
 
 
 
 
 
 
Microsatellite instability pathway (MIN) 
Figure 2  CIN and MIN pathways (modified from Chung 2000) 
Normal 
epithelium 
APC
K-ras
p53 18q LOH 
 DNA MMR genes 
(MLH1, MSH2, 
MSH6, PMS2) 
 TGFβRII, BAX, 
IGF2R, E2F4, 
TCF4 
Early 
adenoma 
Late 
adenoma 
Carcinoma 
APC
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The MIN model is associated with a mutator phenotype and entails 
three intercellular mechanisms.  These mechanisms are:  nucleotide 
excision repair (NER), base excision repair (BER), and mismatch 
repair.  A hallmark of the MIN pathway is the instability of the 
microsatellites (Aaltonen et al. 1993; Ionov et al. 1993; Thibodeau et 
al. 1993), which will be described later. 
HNPCC features are clinically similar to those of microsatellite 
instable (MSI) tumors.  These are: the proximal location of the tumors, 
mucinous/undifferentiated tumors, infiltration of lymphocytes, and 
improved prognosis.  An unsurprising 85-95% of HNPCC tumors are 
microsatellite instable, whereas only 15% of sporadic tumors are.  
Microsatellites, also called short-tandem repeats, are often 
polymorphic DNA loci that contain a repeated nucleotide sequence, 
such as CAn and An. The MSI phenomenon is characterized by 
numerous extra alleles in the microsatellite markers.  It indicates a 
malfunction in the mismatch repair system and occurs more commonly 
in proximal tumors.  
Since 1996 (Rodriguez-Bigas et al. 1997), MSI status can be 
determined using the Bethesda guidelines, a reference panel of five 
microsatellite markers.  A tumor is considered MSI+ if at least two out 
of five markers are positive, otherwise it is classified as stable.  These 
guidelines have since been revised at an HNPCC workshop held in 
Bethesda, Maryland in 2002 (Umar et al. 2004).  The new guidelines 
suggest the use of additional microsatellite markers with 
mononucleotide repeats, BAT40 and/or MYCL, if only the dinucleotide 
repeats of the original panel are positive (table 4). 
 
Table 4  Bethesda guidelines (updated addition in bold) 
            
Dinucleotide markers D5S346 D2S123 D17S250
BAT markers BAT25 BAT26 BAT40
Others MYCL
Microsatellite markers of Bethesda guidelines
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1.2.3. Mechanisms of Microsatellite Instability 
 
Microsatellite instability occurs when nucleotide repeats expand 
past a critical number. The underlying mechanism behind this is the 
inactivation of the DNA mismatch repair system.  In 1971, Knudson et 
al. postulated that inactivation of a tumor suppression gene could be 
accounted for by a two-hit mechanism, in which two separate 
mutations occur in the same gene, rendering it incapable of 
functioning.  This seems to hold true for the DNA mismatch repair 
gene inactivation as well (Hemminki et al. 1994).  In hereditary 
cancers, like HNPCC, a germline mutation in either MLH1 or MSH2 is 
the first hit leading to disease.  This may then be accompanied by 
either the loss of the wild-type allele, known as loss of heterozygosity 
(LOH), or its mutation (Hemminki et al. 1994; Konishi et al. 1996; 
Tannergård et al. 1997; Chung et al. 2003).  In sporadic MSI cases the 
two hits are not so obvious, these cancers display a lower frequency of 
LOH as well as somatic MLH1 and MSH2 mutations.  Sporadic MSI 
tumors, however, frequently have hypermethylation of the MLH1 
promoter region (Kane et al. 1997; Cunningham et al. 1998; Herman et 
al. 1998).  This may possibly account for MLH1 inactivation in these 
tumors.  The MSH2 gene promoter, however, does not show 
hypermethylation (Cunningham et al. 1998; Herman et al. 1998). 
 
1.2.4. Tumor Spectrum 
 
HNPCC is a multi-organ cancer syndrome with tumors mainly 
occurring in the colon or the endometrium. In some families 
endometrial cancer may even be more common than colon cancer 
(Aarnio et al. 1999).  The tumor spectrum, however, also includes 
gastric, small bowel, hepatobiliary tract, upper urologic tract, ovarian, 
and brain cancer (Watson and Riley 2005). Since all cells have 
inherited a copy of a defective DNA mismatch repair gene, resulting in 
hypermutability, why then are only some tissues involved.  
Endometrial cancer observations suggest that there may be a 
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differential role of different predisposing mutations.  A study by Duval 
et al. (2002) showed that gastric and colorectal cancers had similar 
mutation profiles but that they differed from those of endometrial 
cancer.  The occurrence of endometrial carcinoma in HNPCC appears 
to be connected predominantly with mutations in MSH2 and MSH6 
(Wijnen et al. 1999).   
 
 
1.3. GENETIC BASIS OF ENDOMETRIAL CANCER 
 
The most common gynecological cancer in the United States is endometrial 
carcinoma.  Although, like colon cancer, endometrial cacner mostly arises as a 
sporadic disease, it may also be a part of certain hereditary syndromes.  This 
cancer is likely a constituent tumor of Cowden syndrome, an autosomal dominant 
disorder distinguished by multiple hamartomas, as well as thyroid and breast 
cancer risk (Eng 2000). An estimated 80% of CS is associated with PTEN 
germline mutations (Marsh et al. 1998), as well as an additional 60% with 
Bannayan-Riley-Ruvalcaba (BRR) syndrome, up to 20% with Proteus syndrome 
(PS), and roughly 50% with Proteus-like syndrome (Eng 2003).  The phosphatase 
PTEN, classified as a tumor suppressor, mediates cell arrest and apoptosis by 
signaling down the phosphoinositol-3-kinase/Akt pathway (Furnari et al. 1998; Li 
et al. 1998; Maehama and Dixon 1998; Stambolic et al. 1998; Weng et al. 1999, 
Vivanco and Sawyers 2002).  Somatic mutations and deletions, affecting 
expression of this gene, occur in as much as 93% (Mutter et al. 2000) of 
endometrial carcinomas with endometrioid histology, and evidence suggests it 
may even be a gatekeeper for endometrial carcinoma since PTEN function loss 
occurs in the very early stages of tumor development (Levine et al. 1998). 
DNA mismatch repair defects, leading to microsatellite instability, are found 
in 20-30% of sporadic endometrial carcinomas.  Endometrial carcinomas are the 
most common malignancy in female HNPCC patients and MSI is a common 
feature of HNPCC.  Though MSI tumors were originally supposed to harbor a 
higher frequency of somatic PTEN mutations than MSS tumors, studies have now 
shown that there are similar frequencies for both (Nassif et al. 2004).  About 19% 
of sporadic MSI colorectal carcinomas have somatic PTEN frameshift mutations 
 21
almost solely in the two 6(A) tracts of exons 7 and 8, whereas no more than 5% 
of MSI unknown or MSS colorectal carcinomas do, though none in the poly(N) 
tracts (Guanti et al. 2000).  
 
 
1.4. DNA METHYLATION IN NORMAL AND CANCER DEVELOPMENT 
 
1.4.1. Vertebrate Methylation  
 
In vertebrates, DNA methylation, that is the addition of a methyl 
group to the internal cytosine of a CCGG sequence of CpG islands, 
occurs in promoter regions which are located 5' to many genes that 
are rich in CG content.  A number of important genome functions are 
affected by DNA methylation, including the control of gene 
expression during development and differentiation, as well as 
provision of a transcriptional backnoise reduction mechanism (Bird 
1986; Razin and Kafri 1994).  DNA methylation provides a post-
replicative addition of a methyl group, and is therefore epigenetic in 
nature providing for both fidelity, due to symmetry of the CpG target 
sequence, and flexibility. The semi-conservative nature of DNA 
replication ensures flexibility, allowing for hemi-methylated CpG 
sites to persist or be methylated (Laird and Jaenisch 1996).  If no 
methylation occurs, however, then an acquired altered methylation 
pattern will arise in one of the two daughter strands upon the next 
replication.  
Promoter DNA methylation causes gene expression to be 
repressed.  Two proposed mechanisms may explain this repression.  
The first, though not all transcription factors fit the necessary 
structure, suggests a sequence-based direct inhibition of transcription 
factors (Tate and Bird 1993).  The second entails the non-sequence-
specific binding to methylated DNA by proteins from the MBD 
family, that is MeCP1 and MeCP2 (Boyes and Bird 1992).  This 
protein family also contains a transcriptional repression domain 
which, when bound to the DNA, forms a complex with core 
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repression molecules and histone deacetylase proteins; thereby, 
compressing chromatin structure making it less accessible to active 
transcription (Nan et al. 1997; Bestor et al. 1998; Jones et al. 1998).  
A combination of these two mechanisms probably occurs in vivo.   
 
 
1.4.2. DNA Methyltransferases 
 
DNA methyltransferases are responsible for two distinct patterns 
of methylation.  These are maintenance activity, which is sequence 
specific and restores full methylation of hemi-methylated CpG sites, 
and de novo methylation activity, wherein a previously unmethylated 
target sequence is methylated. 
Originally only one DNA methyltransferase enzyme was 
identified and cloned in both mice and humans, DNMT1.  This is a 
large enzyme containing a C-terminal catalytic domain, akin to that 
found in prokaryotes, and a large N-terminal regulatory domain, 
which targets replication foci in addition to other functions 
(Leonhardt et al. 1992).  Highly conserved in eukaryotes (Yen et al. 
1992), DNMT1 is extremely affinitive to hemi-methylated DNA, 
permitting parental DNA pattern duplication in daughter strands 
through its N-terminus domain targeting capability.  Removal of this 
domain results in de novo methylation (Bestor 1992), and was 
originally considered as the de novo methylation mechanism.   
The second possible responsible enzyme for de novo methylation 
appeared to be another methyltransferase enzyme, suggested in a 
study by Lei et al. (1996).  In their study, embryonic stem cells 
exhibited de novo methylation despite being null for DNMT1.  This, 
in addition to the inexplicability of the role DNMT1 plays in tumor-
specific methylation abnormalities, drove the search for additional 
DNMT’s.  Two groups (Okano et al. 1998a; Yonder and Bestor 1998) 
isolated a prospective second enzyme, DNMT2, but it did not exhibit 
any methylation ability.  Shortly after this, a third potential enzyme 
group including DNMT3a and b, however, was isolated by Okano et 
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al. (1998b) in a database search. Another member of this group is 
DNMT3L, a nonenzymatic protein, originally found by Aapola et al. 
(2000), and further characterized by Aapola et al. (2001), Hata et al. 
(2002), and Deplus et al. (2002).  These proteins, though down 
regulated in differentiated embryonic stem cells and adult murine 
tissue, are expressed in undifferentiated embryonic stem cells at 
elevated levels.  Moreover, they proved equally proficient in 
methylation of both hemi-methylated DNA and unmethylated DNA.  
Further studies confirmed that DNMT3a and b are essential for de 
novo methylation and development (Okano et al. 1999; Kaneda et al. 
2004), but their methylation activity is stimulated by DNMT3L 
(Suetake et al. 2004).   
Ramchandani et al. 1999 described putative demethylase activity 
but it has been studied far less extensively than its counterpart.  The 
proposed demethylase enzyme seems to bind specifically to the CpG 
dinucleotide, regardless of whether the DNA is fully or hemi-
methylated. 
 
1.4.3. Role of Methylation in Normal Development 
 
DNA methylation is necessary for normal mammalian 
development.  During development and gametogenesis three distinct 
phases are manifested: demethylation, de novo methylation, and 
maintenance methylation.  Preimplantation embryos undergo a wave of 
genome-wide demethylation during cleavage.  Widespread de novo 
methylation, establishing overall methylation patterns, then occurs 
prior to gastrulation.  This pattern is preserved in the somatic cells, 
throughout life (Monk et al. 1987, Kafri et al. 1992), while the 
embryonic lineage maintains lower methylation levels (Jaenisch 1997). 
Li et al. (1992) demonstrated that methylation is undeniably 
essential for development.  Despite mutated homozygous Dnmt1 
embryonic stem cells being viable, even with only trace levels of DNA 
methyltransferase activity, introduction of the same mutation into the 
germline of mice caused a recessive lethal phenotype with successive 
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homozygous embryos not developing past mid-gestation.  These 
observations are supported by previous studies which showed that both 
preimplantation and undifferentiated embryonic stem cells have high 
de novo methylation activity levels (Jaenisch 1997).  No evidence of 
this de novo methylation is discernible after gastrulation and 
differentiation; low levels, however, can be detected in somatic cells.  
Although this process is slow and inefficient in targeting genes for 
silencing, it could provide a selective advantage for tumor growth 
(Laird et al. 1995). 
 
1.4.4. DNA Methylation and Evolution  
 
Genome size of free-living organisms has increased from a few 
thousand genes in prokaryotes, to 7,000-25,000 genes in invertebrates, 
up to 30,000-100,000 genes in vertebrates (Olivier et al. 2001; Venter 
et al. 2001).  This increase in gene number and complexity is the 
foundation for the first of two hypotheses concerning the evolutionary 
role of DNA methylation, which suggests that since tissue-specific 
genes have increased, a high efficiency of repression of those genes 
must also exist.  In eukaryotes, repression and transcriptional noise 
reduction are foremostly attributed to the nuclear envelope and 
histones.  Since vertebrate eukaryotes have even more genes than 
invertebrate eukaryotes there must be additional repression 
mechanisms, one of which could be DNA methylation.  Invertebrates, 
indeed, have only a few methylated CpG dinucleotides whereas, 
excluding CpG islands, most, 60-90%, are methylated in vertebrates 
(Kress et al. 2001).  These methylated CpG dinucleotides may function 
as a global repression and transcriptional noise reduction layer (Bird 
1995).  The second theory views DNA methylation as a nuclear host-
defense system.  Since cytosine methylation may cause promoter 
inactivation of most viruses and transposons, including retroviruses 
and Alu elements (Yoder et al. 1997), it is useful in the fight against 
possible threats by endogenous parasitic mobile genetic elements in 
mammals.  
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1.4.5. DNA Methylation and Cancer  
 
DNA methylation is an ideal participant in the multi-step process 
by which normal cells develop into malignant cells.  Two basic 
methylation patterns are observable in tumor cells, namely, global 
genome hypomethylation, which apparently begins early on in tumor 
development (Christman et al. 1993; Pogribny et al. 1997), and 
targeted hypermethylation of specific regions.  Tumorigenesis 
transpires by either a genetic or epigenetic system of DNA 
methylation, as described below.   
 
1.4.5.1. Genetic System 
 
The 5’methylcytosine residues within CpG pairs are highly 
mutable.  This is possibly a consequence of the increased 
deamination rate of 5’mC to T; three factors influence repair of 
this lesion. 
First, cytosine deamination forms the base uracil, but 
deamination of 5’mC forms the base thymine.  Uracil does not 
naturally occur in DNA and is therefore more easily recognized 
for correction by uracil DNA glycosylase than other DNA 
glycosylases recognize errant thymine (Jiricny 1996).  This 
results in an increase of CpG to TpG mutations or, on the 
opposite strand, CpG to CpA mutations. 
The second and third factors are less complicated.  
Deamination rate is reasonably constant and thereby sufficient to 
account for observed dsDNA mutations (Shen et al. 1994).  
Finally, compared to unmethylated cytosine, 5’mC has an 
enhanced mutability in cell division thereby making it more 
vulnerable to mutation in cancer, in which an increase in cell 
division occurs (Lieb and Reihmat 1997).   
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1.4.5.2. Epigenetic System 
 
The effect of epigenetic mechanisms of DNA methylation on 
gene activity is difficult to study.  DNA methylation allegedly 
affects chromatin structure.  Whether the structure is affected by 
increased affinity of methylated DNA for Histone H1, as 
proposed by Campoy et al. (1995), or by physical binding of 
Histone H1 determining the methylation levels is, however, 
debatable. 
Several pieces of evidence demonstrate that transcription 
repression of hypermethylated promoter sequences is directly 
caused by DNA methylation.  This evidence includes the Min 
mouse model (Laird et al. 1995), retinoblastoma (RB) gene 
promoter region methylation effects (Stirzaker 1997), and the 
high promoter hypermethylation frequency in microsatellite 
unstable sporadic colon cancers of the MMR gene MLH1. 
Using a combination of methods, Laird et al. (2003) 
determined the effect of DNA methyltransferases in ApcMin mice 
with induced intestinal neoplasia.  Reducing the methylation level 
of these mice through reduction of methyltransferase activity 
reduced the amount of polyps in the test mice compared to the 
control mice.   
Second, the RB gene promoter methylation, the first identified 
with methylation silencing, is documented in familial cases of 
unilateral retinoblastoma.  In addition, in vitro tests show that the 
methylation of this promoter blocks the promoter activity of the 
RB gene. 
Third, in sporadic microsatellite unstable colon cancers the 
promoter region of the MLH1 mismatch repair gene is frequently 
methylated (Herman et al. 1998).  Plumb et al. (2000) and 
Herman et al. (1998) found that MLH1 methylation is a reversible 
phenomenon.  Treating cell lines with the demethylating agent 5’-
aza-2’deoxycytidine (5-aza-dC) substantially increases the MLH1 
expression after five days of treatment.  This observation has 
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important implications.  Treatment of cell lines, derived from 
MLH1 deficient tumors, with the DNA methyltransferase 
inhibitor 5-aza-dC results in demethylation of the MLH1 promoter 
and ultimate restoration of MMR activity, indicative of the 
primary nature of the inactivation of MLH1 by CpG island 
hypermethylation.  Since MMR deficient tumors are resistant to 
alkylating agents used for chemotherapy, this may also be 
clinically important.  Plumb et al. (2000) showed that after 5-aza-
dC treatment these tumors become resensitized to such drugs. 
Finally, when studying p16INK4a, Myöhänen et al. (1998) 
observed that if one copy of a tumor suppressor gene is mutated 
or lost, then the remaining wild-type gene copy is more readily 
hypermethylated, resulting in inactivation.  All these observations 
provide evidence that a primary contributing factor in 
tumorigenesis is DNA methylation. 
The mechanism by which DNA methylation occurs in the 
above-described events is still unclear, though the methylation 
machinery itself may contribute to this process.  As demonstrated 
in the Min mice experiments, the DNA-Mtase activity level has a 
direct effect on the number of polyps in neoplastic intestinal cells. 
 
1.4.6. Methods to Study DNA Methylation 
 
Different methods of studying DNA methylation exist (table 5).  
These methods allow for the study of different aspects of methylation, 
including global vs CpG island methylation, and may even allow for 
analysis of the alleles separately.  Knowing which of the two alleles is 
methylated is sometimes important, for example when one examines 
the first and second “hits” in cancer.  For this purpose, one may use 
closely linked polymorphisms as allele-specific markers (Myöhänen et 
al. 1998). 
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Table 5  Most commonly used laboratory methods to study DNA methylation 
(adapted from Laird 2003). 
Technology Methylation discrimination principle Application
Southern blot restriction digestion quantitative analysis
HpaIIPCR restriction digestion qualitative analysis
COBRA bisulphite conversion quantitative analysis
MSP bisulphite conversion sensitive detection
Technology Methylation discrimination principle Application
SssI methyl acceptance assay DNA methyltransferase substrate global methylation analysis
RLGS restriction digestion marker discovery
Epigenomics microarray bisulphite conversion disease stratification
I Methylation of CpG sites in specific genes
II Global DNA methylation
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2. AIMS OF STUDY 
 
• Characterization of hereditary nonpolyposis colon cancer (HNPCC) 
versus sporadic colon cancer in relation to tumorigenic mechanisms. 
 
o What mechanisms underlie microsatellite instability (MSI) in 
sporadic colorectal cancers? 
o What is the prevalence of DNA methylation changes in colorectal 
cancer and how do these changes correlate with MSI?  
 
• Comparison of endometrial carcinoma and colorectal carcinoma with 
similar underlying inherited mutations, in relation to microsatellite status 
and target genes. 
o To which extent do somatic alterations in target tissue explain the 
HNPCC tumor spectrum? 
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3. MATERIALS AND METHODS  
 
3.1. PATIENT SAMPLES (I-IV) 
 
Patient samples used in studies I and II were primarily derived from a 
prospective collection of 509 unselected colorectal adenocarcinomas harvested at 
nine large regional hospitals in Southern Finland between May 1994 and April 
1996 (Aaltonen et al. 1998).  The samples represented fresh-frozen or paraffin-
derived normal colonic mucosa or tumor tissue.  To ensure the sections used for 
DNA extraction had the highest possible tumor cell percentage all specimens 
were examined histologically.   
We included all tumors (n=51) demonstrating high MSI and no germline 
mutations (MLH1 or MSH2) by direct sequencing (I and II).  Additionally, we 
analyzed 38 MSS tumors selected randomly, except for equal numbers of 
proximal and distal tumors (I), and 21 HNPCC patients with known germline 
mutations, MLH1 n=20 and MSH2 n=1 (II).  
Study III and IV involved samples derived from known MLH1 and MSH2 
germline mutation carriers. In study IV we analyzed a total of 44 colon cancers 
and 57 endometrial cancers, including cancer samples of both tissues in eight 
patients.  Both groups had similar germline mutation distributions.  Study III 
included only endometrial cancer patients. Samples consisted of paraffin-
embedded tissue or blood, with known MLH1 or MSH2 germline mutations 
(n=41), as well as aberrant PTEN-expressing tumors (n=20), (see table 6 for the 
list of germline mutations).   
All studies were approved by the local ethics committees. 
 
Table 6  MLH1 and MSH2 germline mutations included in present study. 
Gene Mutation # Type of mutation
1 3.5 kb genomic deletion affecting codons 578–632 of exon 16
2 G>A at 454–1 at splice acceptor of exon 6
3 G>C at 1976 (codon 659) of exon 17
4 G>C at 1409 + 1 at splice donor of exon 12
5 T>G at 320 (codon 107) of exon 4
6 G>A at 1039–1 at splice acceptor of exon 12
7 G>T at 1559–1 at splice acceptor of exon 14
8 C>T at 1975 (codon 659) in exon 17
MSH2 9 CA deletion at 1550 (codon 518) of exon 10
M
LH
1
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3.2. DNA METHYLATION (I AND II) 
 
We applied a PCR-based assay relying on the inability of the HpaII restriction 
enzyme to cleave CCGG sequences with an internal methylated cytosine.  At the 
MLH1 promoter region there are four HpaII sites located at 567, 527, 347, and 
341 relative to the initiation codon.  Using flanking primers, we studied each site 
individually, with the exception of the latter two sites, which, due to their close 
proximity were a single reaction.  In addition to an HpaII digestion of each 
sample, we included both an undigested DNA control, to verify amplification, 
and an MspI digestion, an isoschizomer to HpaII insensitive to methylation, used 
to verify the presence of the methylation site. We determined the optimal number 
of PCR cycles to be the amount at which a detectable band was visible from the 
undigested template, but no bands from DNA digested with MspI.  For 
comparison we studied a functionally neutral gene, calcitonin, analyzing region V 
of the gene promoter as described in Heiskanen et al. (1994).  The protocols for 
restriction digestions and PCR analyses can be found in the original articles.  
 
 
3.3. IMMUNOHISTOCHEMISTRY (I-III) 
 
Using mouse monoclonal antibodies against the full-length human MLH1 
protein (clone G168-728 from PharMingen, San Diego, CA), we studied the 
expression of the MLH1 protein in the sporadic colon cancer samples (I, II).  
Additionally, we used a monoclonal antibody against the full-length MSH2 
protein (clone G219-1129 from PharMingen) in study II.  The method for the 
staining of these different slide sets varied in relation to what lab they were 
analyzed in.  In general, however, we used paraffin-embedded tissue which was 
first stained with a primary antibody, followed by a secondary antibody before 
counterstaining and photographing.  See original articles for specific protocols. 
To study the expression of the PTEN protein in the endometrial cancers in 
study III we used the specific monoclonal antibody 6H2.1 raised against the last 
100 C-terminal amino acids of PTEN (Ziebold and Lees, unpublished). We 
conducted immunohistochemical staining, using paraffin-embedded tissue and a 
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two step primary and secondary antibody staining method previously described in 
Mutter et al. (2000) and Perren et al. (1999).  
 
 
3.4.  MUTATION ANALYSIS (II-III) 
 
3.4.1. MLH1 and MSH2 Somatic Mutations (II)  
 
Using two-dimensional DNA electrophoresis methods, described 
by Wu et al. (1997), we screened 31 sporadic colorectal cancers and 
two HNPCC cases for MLH1 and MSH2 somatic mutations.  
 
3.4.2. PTEN Mutations (III)  
 
On DNA from 20 HNPCC-related endometrial carcinomas with 
either absent or weak PTEN expression we preformed mutation 
analysis, using PCR-based denaturing gradient gel electrophoresis 
(DGGE) and semi-automated sequencing described by Mutter et al. 
(2000), of all nine exons, exon-intron junctions, and flanking intronic 
sequences. 
 
 
3.5. LOSS OF HETEROZYGOSITY (LOH) ANALYSIS (II) 
 
We used radioactive PCR amplification of microsatellite markers to 
determine LOH (Peltomäki et al. 1993) and scored all cases with either an absent 
or greatly reduced allele in tumor vs normal DNA as LOH.  We considered all 
cases exhibiting homozygosity in the normal tissue, for a given marker, as well as 
those with instability in the tumor DNA to be uninformative.   
For MLH1 we used three microsatellite markers previously shown to have the 
highest deletions rates.  Two of the markers, D3S1029 and D3S1283, flank the 
MLH1 gene at 5cM distance on either side (Hemminki et al. 1994), while marker 
D3S1611 is located in intron 12 (unpublished data). 
For MSH2 we used the markers D2S2259 and D2S123 which encompass the 
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region of 9cM around MSH2. Additionally, we also used a marker flanked by the 
previously mentioned markers, D2S391.  
 
 
3.6. MICROSATELLITE INSTABILITY ANALYSIS (IV) 
 
We studied a total of 14 repeat markers in 12 genes, two genes had two 
separate repeat markers.  Repeats were located in either growth regulation genes 
or DNA repair genes.  Many of them are known to be involved in sporadic 
cancers (Parsons et al. 1995b; Malkhosyan et al. 1996; Souza et al. 1996; Hoang 
et al. 1997; Rampino et al. 1997; Zhou et al. 1997).  See table 7 for the list of 
genes and their repeats.  In total we studied three noncoding and nine coding 
mononucleotide repeats, plus two dicnucleotide repeat markers.  For primer 
sequences and conditions see original publication. 
 
Table 7  Microsatellite repeat markers 
Type of marker Locus Repeat
BAT25 A25
BAT26 A26
BAT40 A40
MSH6 C8
MSH3 A8
IGF2R G8
BAX G8
TGFbRII A10
MLH3 A8, A9 
A6 repeat in exon 7
A6 repeat in exon 8
D3S1611 located within MLH1
CA7 located close to MSH2
noncoding 
mononucleotide 
repeat markers
coding 
mononucleotide 
repeat markers
PTEN
dinucleotide repeat 
markers  
 
 
3.7. STATISTICAL ANALYSIS (I-IV) 
 
To assess differences between the groups we used Fisher's exact test and 
the t-test.   
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4. RESULTS  
 
4.1. DESCRIPTION OF TWO MAIN EPIGENETIC PHENOTYPES FOR 
COLORECTAL CANCER (I) 
 
4.1.1. DNA Methylation Patterns and Correlation with Microsatellite 
Instability 
 
We observed two distinguishable DNA methylation patterns at the 
MLH1 promoter region. Hypermethylation, methylation of tumor tissue 
but not normal mucosa, and hypomethylation, methylation of normal 
mucosa but not tumor tissue.  Of all sporadic colon cancers a majority, 
65/89 (73%), demonstrated altered DNA methylation patterns with 
respect to normal mucosa (fig. 3).  Hypermethylated cases usually 
showed methylation in all three MLH1 fragments studied, while only 
one or two fragments, chiefly fragment 3, showed normal tissue 
methylation in the hypomethylation cases.  Occasionally we found a 
“mixed” pattern which displayed hypermethylation in one or more of 
the fragments while another fragment showed hypomethylation. This 
particular pattern could reveal intratumoral heterogeneity, a proposed 
characteristic of mismatch repair deficient tumorigenesis (Habano et al. 
1998a).  
The development of microsatellite instability in colorectal tumors 
may occur through the inactivation of the mismatch repair gene MLH1.  
We evaluated, through this gene, the role played by methylation in 
colorectal carcinomas and also studied a functionally neutral target 
gene for methylation, calcitonin.  We found that two patterns of DNA 
methylation correlated quite closely with the MSI status of the tumors.  
Most MSI cases, 31/51 (61%), exhibited methylation absence in 
normal mucosa and presence in tumor tissue, hypermethylation.  In 
MSS cases, the opposite was true: 20/38 (53%) of the cases showed 
methylation only in normal mucosa, hypomethylation. 
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Figure 3  Patterns of methylation observed in MSI (n=51) and MSS (n=38) cases.  
The numbers 1, 2, and 3 refer to the methylation targets within the MLH1 promoter.  
Black box denotes methylated sites; white represents unmethylated sites.  The number 
of MSI vs MSS cases showing a given methylation pattern in normal and tumor DNA 
is indicated below each column. 
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A known silencing method is methylation triggered by DNA 
repetition (Selker 1999), and consequently microsatellite length and/or 
configuration alterations caused by DNA mismatch repair deficiency 
might induce hypermethylation.  If true, and microsatellite instability is 
a primary inducing factor, then all MSI tumors regardless of etiology 
would be expected to be hypermethylated. 
In order to achieve additional insight into the relationship between 
DNA methylation and MSI we evaluated methylation changes in a 
cohort (n=26) of HNPCC patients with germline MLH1 mutations and 
profound MSI phenotype in tumor DNA.  The frequencies for the 
different patterns (table 8) did not support a primary role of MSI in 
methylation changes.  Instead they suggested that promoter 
hypermethylation was a special characteristic of truly sporadic MSI 
colorectal carcinomas. 
 
Table 8  Frequencies of DNA methylation patterns observed in 
colorectal cancers (n=26) from HNPCC cases 
Pattern    Frequency 
    
hypermethylation   23% 
hypomethylation   19% 
mixed   23% 
no change   35% 
 
 
4.1.2. Methylation Specificity 
 
To further understand whether or not the patterns observed in 
MLH1 were restricted to this gene or more widespread, we looked at 
methylation patterns of the calcitonin gene.  We chose this gene for 
comparison because it is a well-characterized methylation target in a 
number of malignancies, including colon cancer, but unlike MLH1 its 
alterations have not been associated with any selective advantage 
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(Baylin et al. 1987; Silverman et al. 1989; Heiskanen et al. 1994; 
Baylin et al. 1998).   
The calcitonin gene was hypermethylated in all MSI cases except 
one. It was also methylated in cases with no MLH1 promoter 
hypermethylation, which is consistent with it being a methylation 
target.  More importantly, a significant fraction, 5/19 (26%) of the 
MLH1 hypomethylated MSS tumors was also hypomethylated in the 
calcitonin gene.   
Our combined findings of MLH1 and calcitonin gene methylation 
support the idea of distinct patterns for MSI and MSS tumors in 
addition to surrounding normal mucosa, though genome-wide 
screening of CpG islands for methylation would need to be performed 
for confirmation. 
 
4.1.3. Correlation with MLH1 Protein Expression 
 
The MLH1 promoter contains at least 23 CpG sites (Deng et al. 
1999) including the four HpaII restriction sites contained in the three 
fragments we studied.  Only some regulate MLH1 protein expression 
through methylation, making it of interest to study whether 
methylation of these sites may have an effect on gene expression in the 
present tumors, and more importantly, normal mucosae.  We analyzed 
available paraffin-embedded samples of MSI tumors for the expression 
of the MLH1 protein by immunohistochemistry.  We considered cases 
in which there were fewer than 25% cancer cells with visible staining 
to have reduced or lost expression of MLH1 protein.  A majority of the 
MSI tumors in which we observed promoter hypermethylation in one 
or more of the three MLH1 sites fell into this category, 30/36 (83%).  
Our results were compatible with those reported by others 
(Cunningham et al. 1998; Herman et al. 1998). 
Of particular interest were the six cases in which we found 
hypomethylation at all three sites (fig. 3, pg. 35).  Of these cases we 
only had four MSS cases available for examination by 
immunohistochemistry.  Severe reduction or loss of protein expression 
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was visible in all of the normal mucosal tissues, while the adjacent 
tumor tissue, which lacked methylation, showed an intense staining 
(see fig. 3, in the original article I).  These observations emphasize the 
pathogenic relevance of methylation changes by showing that the loss 
of MLH1 protein expression accompanies MLH1 promoter 
hypermethylation in both normal mucosa and tumor tissue. 
 
 
4.2. BASIS OF MMR GENE INACTIVATION IN SPORADIC AND 
HEREDITARY COLORECTAL CANCERS (I, II) 
 
4.2.1. Sporadic Colorectal Cancer 
 
As described above, we observed two main types of methylation 
patterns, hypermethylation and hypomethylation, in sporadic colorectal 
cancer. Of the 51 MSI+ cases we analyzed for methylation changes, 31 
cases were hypermethylated (61%), two were hypomethylated (4%), 
five had a mixed pattern (10%), and 13 displayed no change (25%). 
The distribution of the patterns observed in the MSS cases were four 
hypermethylated (11%), 20 hypomethylated (53%), three mixed 
pattern (8%), and 11 no change (38%).  
We obtained an interpretable immunohistochemical analysis (IHC) 
result for a total of 46/51 MSI+ cases.  Of these, 80% showed an 
involvement of the MMR genes MLH1, MSH2, or both.  Loss of or 
reduction of MLH1 expression occurred in 36 of the cases and MSH2 
loss or reduction in seven. 
An overwhelming majority of the cases, 30/36, demonstrated loss 
of MLH1 protein expression in the IHC analysis presented with DNA 
hypermethylation at one or more of the studied CpG islands.  
Methylation of MSH2 was not addressed because we have previously 
found that, unlike MLH1, it is not a methylation target (unpublished 
data).  In addition to methylation changes we also found eight MLH1-
linked tumors and two MSH2-linked tumors with loss of 
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heterozygosity in the respective regions, as well as two somatic 
mutations each for both the MLH1 and MSH2 cases. 
 
4.2.2. Colorectal Cancer with Inherited MMR Deficiency (HNPCC) 
 
Hereditary cases did not display as many methylation changes as 
sporadic cases. Out of 26 MLH1 germline HNPCC cases only six were 
hypermethylated (23%), five were hypomethylated (19%), six had a 
mixed pattern (23%), while nine displayed no change (35%).  All the 
cases, 26 MLH1 and one MSH2 with germline mutations as their first 
hits (see table 6 in Materials and Methods for the list), exhibited 
expression loss of their relevant gene, however. 
In contrast to the frequency of hypermethylation in sporadic cases 
(34/51), only 12/26 MLH1 germline mutation cases tested positive for 
DNA hypermethylation (p=0.003).  We found LOH, however, to occur 
in hereditary cases at a similar rate compared to sporadic cases, 33% 
compared to 24%. 
When we looked at the combined data for both LOH and 
hypermethylation in the two types of tumors we saw that LOH and 
hypermethylation were mutually exclusive, possibly because they have 
similar MLH1 inactivation functions.  All HNPCC tumors already 
carrying a MLH1 germline mutation as their first hit showed, with one 
exception, no hypermethylation in the presence of LOH.  Our one 
MSH2 case had LOH accompanying its germline mutation.  See table 2 
in the original article II for a summary.  While our methylation 
analyses were not allele-specific, the mutually exclusive occurrence of 
LOH and hypermethylation at MLH1 suggests that the wild-type allele, 
rather than the mutated allele, was a favored hypermethylation target. 
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4.3. PTEN IN SPORADIC AND HEREDITARY ENDOMETRIAL CANCERS 
(III, IV) 
 
We used immunohistochemical analysis to assess the PTEN protein 
expression in 41 MMR gene mutation positive endometrial carcinomas from 
HNPCC families. All cases had either stroma and/or normal endometrial 
epithelium which presented with strong PTEN immunostaining in both the 
nucleus and the cytoplasm.  We graded these ++ and used them as internal 
controls for our samples. 
We found a weak (+) or no (-) cytoplasmic PTEN staining in 28/41 (68%), of 
the MMR gene mutation positive endometrial carcinomas from HNPCC families.  
Of these, twelve (29%) had weak PTEN immunostaining and the remaining 16 
(39%) had no immunoreactivity.  
We only had adequate material from 20 of these 28 endometrial carcinomas 
for mutational analysis of the entire PTEN gene.  In 17/20 (85%) of the tumors 
we found 18 frameshift mutations.  Of these, 12 (67%) were in the poly(A) tracts, 
normally consisting of either four, five, or six A-repeats.  Notably, somatic 
insertions or deletions involving one of the two 6(A) tracts in exon 7 or 8 
occurred in ten (56%) cases.  With possibly one exception, each tumor showed 
only one mutant PTEN allele, PTEN mutations were monoallelic.  A total of 
seven cases harboring a monoallelic mutation also showed decreased PTEN 
expression while nine exhibited none.  The remaining negative-expression case 
carried two different mutations. 
When we compared the mutational frequency of PTEN in sporadic versus 
HNPCC-related endometrial carcinomas, we found a significant difference 
between the two groups, P=0.006.  Additionally, the spectral difference between 
sporadic and HNPCC-related endometrial cancers with PTEN mutations was also 
significant, p=0.0009.  Sixty of 118 (51%) sporadic MSI+ endometrial cancers 
had somatic mutations, which included 64 truncating mutations. Of these, 39 
were frameshift mutations, only eight of which (21%) occurred in the 6(A) tracts 
in exons 7 and 8.  Notably, compared to sporadic MSI+ tumors we also found a 
significant over-representation of frameshift mutations in 6(A) tracts of exons 7 
and 8 in HNPCC-related endometrial cancers, p=0.01. 
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In study IV, we compared 57 endometrial cancers and 44 colorectal cancers 
from germline carriers of eight MLH1 mutations and one MSH2 mutation.  We 
found an association with PTEN instability and endometrial cancer.  These 
endometrial cancers, as opposed to colorectal cancers with the same underlying 
germline mutations, were associated with instability in 6(A) tracts of exons 7 and 
8 of PTEN, as discussed below (4.4). 
 
 
4.4. PATTERNS OF MICROSATELLITE INSTABILITY IN ENDOMETRIAL 
AND COLORECTAL TUMORS FROM INDIVIDUALS WITH 
IDENTICAL PREDISPOSING MUTATIONS IN MMR GENES (IV) 
 
We observed distinct MSI profiles for colorectal cancers (n=44) and 
endometrial cancers (n=57) despite the origin of these tumors from carriers of 
identical predisposing mutations.  Most analyzed cases were from carriers of 
either mutation 1 or 2, both common founder mutations affecting MLH1 in the 
Finnish population. 
The predominant pattern exhibited by the colorectal cancers consisted of 
instability in at least one of the noncoding BAT repeats in 89% of the tumors, 
TGFβRII in 73%, at least one dinucleotide repeat in 70%, MSH3 in 43%, and 
BAX in 30%.  Endometrial cancers, however, showed a more heterogeneous 
pattern of instability typically affecting different coding repeats in different 
tumors.  Notably, TGFβRII and PTEN often displayed mutually exclusive 
instability.  See figures 1A and 1B in the original article for a pictorial summary 
of these data. 
When we compared the individual marker loci instability frequencies against 
tumor type TGFβRII turned out to be a “target” gene for colorectal cancers, 
instable in 73% of the colorectal cancer tumors and only 18% of the endometrial 
cancer tumors, p=2.2 X 10-8.  Conversely, PTEN instability occurred in only 5% 
of the colorectal cancers and 20% of endometrial cancers, p=0.04.  We also 
observed a significantly lower proportion of marker instability, average fractions 
of instable markers per tumor, in endometrial cancers, 0.27, than colorectal 
cancers, 0.45, p<0.001.  Though not statistically significant, complete stability 
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occurred in 23% of endometrial cancers while in only 11% of the colorectal 
cancers. 
In addition, endometrial cancer had shorter allelic shifts in the BAT markers 
than colorectal cancers.  The mean basepair deviation in endometrial cancers was 
4.1 for BAT25 (range = 1-7), 8.5 for BAT26 (range = 4-13), and 6.1 for BAT40 
(range = 3-9).  Colorectal cancers had shifts of 6.7 (range = 4-11) for BAT25, 
shifts of 13.5 (range = 9-17), and for BAT26, shifts of 9.6 (range = 3-13).  The 
difference between endometrial cancer and colorectal cancer in all cases was 
significant, p<0.001.  Each tumor showed close correlation of the size shifts of 
the individual BAT markers, with the average size shift in basepair for all 
markers being 5.1 (range = 1-12) in endometrial cancers compared to 9.3 (range 
= 3-16) in colorectal cancers, p<0.001.  See figure 2 in the original article for a 
graphic summary. 
A double diagnosis of both endometrial cacner and colorectal cancer occurred 
for eight of our patients; together they represented five MLH1 germline 
mutations and afforded us supreme circumstances for the comparative evaluation 
of these two cancer types.  These cases combined substantiated our findings for 
the larger group which were: more frequent TGFβRII mutations in colorectal than 
endometrial cancers, 88% compared to 25%, PTEN mutations more common in 
endometrial than colorectal cancers, 25% compared to 13%, instable marker 
proportion per tumor lower in endometrial cancers than in colorectal cancers, 
0.42 vs 0.58, and smaller allelic BAT marker shifts in endometrial cancers vs 
colorectal cancers, 6.1 vs 10.5. 
 
 
4.5. CLINICOPATHOLOGICAL CORRELATIONS (I, IV) 
 
In order to examine their potential relevance to the observed DNA 
methylation phenotypes we evaluated age of diagnosis as well as tumor location.  
We observed a higher incidence of MLH1 promoter hypermethylation with 
respect to age; Miyakura et al. (2001) described a similar phenomenon. 
Methylation rate at the MLH1 promoter region increased as a function of age in 
MSI tumors (mean age of diagnosis, 72 yrs) and also to some degree in the 
normal mucosa.  Examining both categories, age and location together, normal 
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mucosa remained mostly unmethylated, while most tumors were methylated in 
accordance with hypermethylation in tumors relative to normal mucosa.  In MSS 
cases (mean age of onset, 69 yrs) the normal mucosa mostly displayed 
methylation whereas most tumors were unmethylated.  The rate of methylation 
increased with age in a similar, yet reversed, way as it did in MSI cases (fig. 2B, 
in original article I).   
We also examined if developmental and biological differences associated 
with the location of tumors, proximal compared to distal, might influence the 
susceptibility to neoplastic transformation (Bufill 1990).  We more commonly 
found MLH1 promoter region methylation in MSI cases among the proximal 
tumors than distal tumors (79% compared to 44% respectively, p=0.05), while, 
regardless of location, the normal mucosa methylation was approximately 30% 
(table 2, in original article I).  In MSS cases, the proportion of promoter 
methylation in the normal mucosa increased from distal (55%) to proximal 
(78%), though this was not statistically significant.  The methylation, however, 
was about 30% regardless of the location of the tumor.  On the basis of these 
observations it would seem that the hypermethylation phenotype is associated 
with proximal location.  The comprable rate of the normal mucosa methylation in 
both proximal and distal locations of MSI cases, however, argues against a simple 
physiological basis but implies that methylation tendency, MSI status, and 
proximal location all have a mutual etiological denominator. 
In study IV, performed on HNPCC tumors, we looked at the correlation 
between small allelic shifts at BAT loci and tumor stages.  We found no 
distinction of colorectal and endometrial cancers based on clinical stage, 
according to the Dukes and International Federation of Obstetrics and 
Gynecology (FIGO) classification, since most were diagnosed at local stages, 
typical of HNPCC.  According to their histological grade, however, the two 
tumor sets differed greatly.  Colon cancers were mostly, 44%, poorly 
differentiated, grade 3, while only 22% of endometrial cancers presented as grade 
3 and most were either moderately or well-differentiated, grades 1 to 2. An 
increase in tumor grade was directly correlated to the average basepair size shift. 
Colon cancers with grades 1 to 2 had on average a 9 bp shift while those with 
grade 3 had an 11 bp.  Endometrial cancers had a 5 bp shift with grades 1 to 2 and 
a 7 bp with grade 3. 
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5. DISCUSSION  
 
Our aim was to characterize hereditary nonpolyposis colorectal carcinoma vs 
sporadic colorectal carcinoma, as well as HNPCC cases with different inherited 
mutations in relation to methylation status, somatic mutation, loss of 
heterozygosity, and protein expression loss.  In addition, endometrial carcinoma 
and HNPCC cases with the same underlying genetic mutations were compared to 
determine similarities and differences in relation to the microsatellite status of 
their target genes, in particular PTEN mutations instable vs stable tumors. 
 
5.1. ROLE OF DNA METYLATION IN COLORECTAL TUMORIGENESIS (I) 
 
We found evidence, in sporadic colorectal cancer tumors and the neighboring 
normal mucosa, for the existence of two distinct epigenetic phenotypes.  First, a 
“hypermethylator phenotype” (methylation in tumor tissue and lack of 
methylation in normal mucosa) was apparent predominantly in MSI tumors as 
outlined by Ahuja et al. (1997) and Toyota et al. (1999) and further supported by 
Xiong et al. (2001). Second, and more importantly, we identified a previously 
uncharacterized phenotype in which normal mucosa exhibits methylation but 
tumor tissue is free of methylation.  This phenotype occurred primarily in 
sporadic MSS colorectal carcinomas. The latter phenotype may apply to most 
colorectal cancers because, of all cancers of the large bowel and rectum, 85% are 
MSS.   
Although our discovery of methylated CpG islands of autosomal genes in the 
normal mucosa was unexpected, it is not unheard of.  Using similar methods, 
Gonzalez-Zulueta et al. (1995), reported the phenomenon of methylated normal 
mucosa and corresponding expression loss for the tumor suppressor gene 
p16/CDKN2 in a high proportion of colon cancer cases.   Unlike in our study, the 
microsatellite status of the tumors was not noted, however.  Another investigation 
(Toyota et al. 1999) appears to disagree.  They reported an absence of 
methylation in normal mucosa at MLH1 and p16 regardless of microsatellite 
status.  This discrepancy may be due to differences in methodology (restriction 
enzyme assay vs bisulphate modification), analysis of different CpG sites (Deng 
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et al. 1999), or regional differences in the methylation status of the normal 
colonic mucosa.  All of our four normal specimens showing hypermethylation 
and gene silencing were adjacent to the respective tumors and we made no 
attempt to determine whether the methylation changes in the colon were limited 
to the immediate vicinity of the tumors or were more widespread.  The 
methylation of the MLH1 promoter may affect an extended portion of the colon, 
but with a patchy pattern (Nakagawa et al. 2001). 
Differing developmental pathways may exist for MSI and MSS tumors.  In 
MSI tumors, one of the key targets is likely to be the mismatch repair gene 
MLH1. Hypermethylation of this gene may be followed by a cascade of 
mutations in various growth-regulatory genes (Malkosyan et al. 1996 and 
Percesepe et al. 1998), which allow for the proliferation of mismatch repair-
deficient clones.  As for MSS tumors, other genes, like p16 (see above) or APC 
(Hiltunen et al 1997), may be among the main targets for hypermethylation in the 
normal mucosa surrounding the tumors.  The loss of the MLH1 protein in the 
normal mucosa adjacent to MSS tumors suggests that MMR deficiency may have 
played a role in the development of even these tumors.  If so, the different 
microsatellite instability phenotypes may have been selected for at a later stage in 
development.    This cannot, however, be presently determined for sure, since the 
timing of the methylation events remains unknown. 
A close association of microsatellite instability and MLH1 promoter 
hypermethylation emerges from studies including Herman et al. (1998), Kane et 
al. (1997), Cunningham et al. (1998), Veigl et al. (1998), and Shannon and 
Iacopetta (2001).  According to the results of these studies and our study, MSI 
tumors appear to arise from the silencing of the mismatch repair gene MLH1 via 
promoter hypermethylation.  In light of the similar methylation patterns in the 
functionally neutral calcitonin gene and the occurrence of methylation in tumors, 
as well as in normal mucosa, one may hypothesize that methylation precedes 
other genetic and epigenetic events and clonal selection.  Further support for the 
notion of methylation as an early event in tumorigenesis is provided in a number 
of recent studies including Costello et al. (2000) and Toyota et al. (2000). 
We observed a higher incidence of MLH1 promoter hypermethylation with 
respect to age.  The importance of MLH1 promoter region methylation as a 
function of age is further supported by Nakagawa et al. (2001), who showed that 
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patients over 80, compared to patients under 60, had a significantly elevated rate 
of MLH1 promoter hypermethylation.  This elevated rate with respect to age may 
represent a cellular response to environmental carcinogens, from dietary sources 
in this case, as first suggested by Issa et al. (1996) and further substantiated by 
Kim et al. (2001). 
The basis of the biological mechanisms for the epigenetic phenotypes we 
describe are unknown at present.  While we did not conduct any experiments 
addressing this question, other investigators have attempted to explore the basis 
of the altered DNA methylation.  Singal and Ginder (1999) showed that global 
increases and decreases in DNA methylation occur during embryonic 
development and tissue- or gene-specific differentiation.  During these processes, 
two opposing systems are at work.  For increases to occur, a methyl group, 
directed by DNA methyltransferases, is added to a cytosine residue of a CpG 
island.  Decreases in DNA methylation occur when a methyl group is removed, 
through possible demethylase activity (Ramchandani et al. 1999).  A 
phenomenon similar to this may be occurring in tumorigenesis.  Deregulation of 
methyltransferases, which are responsible for the methylation of DNA, may cause 
the methylation changes arising in cancer.  Observations about this matter are, 
however, conflicting.  Eads et al. (1999) found no evidence to support the idea of 
deregulation of methyltransferases, while Kanai et al. (2001) found evidence for 
the involvement of the over-expression of not only DNMT1 but also the recently 
identified de novo methyltransferase, DNMT3b.  Rhee et al. (2002) has since 
showed that the major de novo methyltransferase is DNMT1, despite their 
previous findings that it has little effect on human cancer cells (Rhee et al. 2000).  
They did find, however, that DNMT1 works in cooperation with DMNT3b to 
maintain CpG island methylation.  A novel measuring method of de novo CpG 
methylation activity, described in Jair et al. (2006), has since not only confirmed 
these findings but has additionally shown that DNMT1 may indeed be involved in 
the initiation of promoter CpG island hypermethylation in cancer cells.  Apart 
from possible deregulation of methyltransferases, the mechanisms normally 
guarding CpG islands against access of the methyltransferases may be disrupted 
in cancer (Macleod et al. 1994).  A probable explanation for these different 
observations is that not only a single system is involved, but rather an imbalance 
between several systems. 
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We have, however, studied only the CpG island methylation, which does not 
necessarily correlate with global levels of DNA methylation.  Indeed, by studying 
colorectal mucosa and different colorectal neoplasia for methyl-accepting 
capacity of DNA (Bariol et al. 2003) found that there is no relationship between 
the level of global hypomethylation and CpG island methylation in colorectal 
tumors. 
 
 
5.2. DIFFERENCES AND SIMILARITIES OF TUMORIGENIC 
MECHANISMS IN SPORADIC VS HEREDITARY TUMORS WITH 
MICROSATELLITE INSTABILITY (II-IV) 
 
We found that MSI sporadic colorectal tumors show a predominant 
involvement of MLH1, since most of our cases, 78%, presented with either a loss 
or reduction of MLH1 protein expression while only 15% displayed a reduction 
in MSH2 protein expression.  Supporting our results, Thibodeau et al. (1998) also 
found MLH1 expression reduction in 91% of their MSI-H unselected colorectal 
carcinomas.   
All but three MLH1-linked cases, 92%, had either a genetic or epigenetic 
defect as a possible explanation for expression alteration.  In a small number of 
cases, six (17%), a combination of LOH and/or somatic mutations occurred along 
with MLH1 promoter hypermethylation, which itself occurred in 30 cases, 83%.  
MLH1 promoter hypermethylation is an established effective MLH1 gene silencer 
(Herman et al. 1998; Veigl et al. 1998) and though our analyses were not 
designed to determine if both alleles were affected by hypermethylation, as 
described in previous studies (Veigl et al. 1998), we can conclude that they likely 
are.  If both alleles are definitely affected, then expression changes could be 
explained in most cases by methylation alone, with the minority of cases having 
LOH and/or somatic mutations as second hits. 
Hypermethylation was not addressed as a cause of MSH2 inactivation since 
both Herman et al. (1998) and Cunnigham et al. (1998) found no tendency for it 
in the MSH2 promoter.  We did, however, detect a somatic flaw in two of the 
seven MSH2-associated cases, with one having both a mutated allele as well as a 
lost allele accounting for MSH2 inactivation. 
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Though most sporadic colorectal cases fell into these categories, MLH1 or 
MSH2 associated, some, 13%, showed decreased expression of both.  Half of 
these six cases presented with somatic hits in both MLH1 and MSH2.  In nine 
cases, 20%, however, MLH1 and MSH2 expression remained unaltered despite 
the MSI phenotype.  This could be accounted for in these tumors by one of two 
ways.  First, other genes may account for the MSI, including other MMR genes, 
such as MSH3 or MSH6 (Risinger et al. 1996), the genes encoding DNA 
polymerase delta (da Costa et al. 1995), or exonuclease I (Jäger et al. 2001).  
Second, a mutated nonfunctional protein may be expressed.  Our findings also 
suggest that promoter hypermethylation in sporadic colorectal cancers may be 
viewed as a part of a more widespread hypermethylation predisposition that 
characterizes MSI tumors and is rare in MSS tumors. 
Colorectal cancers from HNPCC patients already have the predisposing 
mutation as the first “hit”.  Worldwide, of all known HNPCC-associated germline 
mutations, MLH1 accounts for 50%, MSH2 for 40%, and MSH6 for 10% 
(Peltomäki and Vasen 2004).  In Finland, due to founder effects, over two-thirds 
of all HNPCC families segregate MLH1 mutations (Holmberg et al. 1998).  
Although in the literature the possibility of a germline “epimutation”, epigenetic 
silencing as a germline event, in MLH1 has been raised (Gazzoli et al. 2002; 
Suter et al. 2004), more data are necessary to confirm these findings.  An 
epigenetic change, however, may serve as a second “hit” in HNPCC–associated 
colorectal tumors, as shown by our study II and the observations by others 
(Esteller et al. 2001).  Yet, in the hereditary MLH1-linked tumors examined by us 
the occurrence of promoter hypermethylation was significantly less than in 
sporadic MSI tumors, displaying reduced MLH1 protein expression.  
Accordingly, the relative share of other types of second “hits”, LOH and somatic 
mutation, may be higher in HNPCC compared to sporadic MSI colorectal 
cancers. 
Despite similar MSI phenotypes in both sporadic and hereditary colorectal 
cancrs, the different hypermethylation prevalence and its possible regulation 
consequences may manifest in pathogenic differences.  A higher proportion of 
sporadic MSI tumors, 83% to 94%, are located proximally compared to HNPCC 
tumors, 70%.  One possible explanation is that preferential tumor formation in the 
proximal colon is connected with a more universal methylation phenomenon 
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(Kim et al. 1994).  For example, the APC gene displays promoter 
hypermethylation particularly in proximal tumors (Hiltunen et al. 1997). 
In sporadic MSI colorectal cancers MLH1 region LOH was associated with 
distal tumors; however, no such correlation emerged in HNPCC.  In published 
studies on sporadic colorectal tumors LOH has been found to be characteristic of 
distal tumors (Delattre et al. 1989).  In HNPCC, the inherent lack of DNA 
mismatch repair may strongly determine tumor location, whereas sporadic distal 
tumors may develop as a result of LOH regardless of microsatellite instability. 
In endometrial cancer, we examined in detail the role played by PTEN, a 
common mutation target in this tumor type. Previous studies on sporadic 
endometrial cancers have shown that PTEN mutation frequency does not 
essentially differ in MSI vs MSS tumors (Kong et al. 1997; Tashiro et al. 1997; 
Simpkins et al. 1998; Gurin et al. 1999; Cohn et al. 2000; Mutter et al. 2000).  
According to our results PTEN inactivation is important in both sporadic and 
HNPCC endometrial tumors, and that the PTEN somatic mutational range and 
incidence in sporadic MSI endometrial cancers differs from that in the HNPCC-
related endometrial cancers. 
Furthermore, we were able to establish the likely chronological sequence of 
somatic PTEN mutations and MMR deficiency.  Frameshift mutations, in PTEN 
occurred in 85% of the HNPCC endometrial cases, with more than half in the two 
6(A) tracts of exons 7 and 8.  Of these tumors, 59% displayed acquired loss of 
MLH1, MSH2, and/or MSH6 protein expression in addition to the loss of MMR 
protein corresponding to the germline mutation, whereas only 33% of tumors 
without somatic PTEN frameshift mutations showed similar results.  Schweizer et 
al. (2001) found that endometrial HNPCC tumors are selectively associated with 
acquired deficiency in the MSH2/MSH6 protein complex.  Our data suggest that 
PTEN frameshift mutations of the 6(A) tracts in exons 7 and 8 are a result of 
serious lack of DNA MMR activity. 
The occurrence of frameshift mutations in sporadic MSI endometrial cancers, 
however, was far less common, showing up in only half of the tumors with a 
mere 20% in the 6(A) tracts.  Schwartz et al. (1999) and Duval et al. (2001) 
showed that mononucleotide frameshift mutations are a phenotypic mark of 
MMR deficiency.  Our observations together suggest that the order of events in 
HNPCC endometrial tumors is: first, germline mutation of one MMR gene, 
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followed by somatic inactivation of other MMR genes, and, finally, somatic 
mutations of other mononucleotide repeats in other genes, for instance PTEN.  
Sporadic MSI tumors may arise in a very different fashion.  Based on our 
observations, they may first exhibit somatic PTEN mutations, which are followed 
by MMR deficiency.  This idea is supported by Mutter et al. (2000 and 2001). 
 
 
5.3. INSIGHTS INTO THE GENETIC BASIS OF THE HNPCC TUMOR 
SPECTRUM (I-IV) 
 
The basis of the tumor spectrum in HNPCC is incompletely understood.  We 
found that both general microsatellite instability patterns and target gene selection 
may influence where a tumor develops in MMR gene germline mutation carriers.  
In regard to the general frequency of MSI, we found a lower percentage of 
instability in endometrial than colorectal cancers from HNPCC patients, 77% vs 
89%, respectively.  Despite the occasional emergence of MMR gene-mutated 
tumors without microsatellite instability, both in mice (de Wind et al. 1998) and 
in humans (Fujiwara et al. 1998), the relativly frequent lack of MSI in our 
endometrial tumors was unexpected because immunohistochemical analysis 
showed MMR protein inactivation corresponding to the germline mutation (see 
figure 1 in article IV; Schweizer et al. 2001).  It is possible, but unlikely, that we 
had normal tissue contamination based on hematoxylin and eosin-stained slides 
that showed tumor percentages of 40% and 50% for stable and unstable 
endometrial tumors  and 60% and 50% for stable and unstable colorectal tumors.  
Intertumoral heterogeneity might offer another explanation.  Despite high tumor 
percentages, microsatellite stable subcolonies may occur in addition to unstable 
ones (de Wind et al. 1998; Habano et al. 1998b; Barnetson et al. 2000), and MSI 
results could depend on which population succeeds.  Tumor “age” may provide 
additional insights.  Janin (2000) and Loeb (2001) proposed that MSI 
carcinogenesis occurs in two phases: first, normal cells lose MMR function 
counterselectively, then progression to malignancy proceeds rapidly provided that 
mutations block apoptosis and senescence.  In line with Tsao et al. (2000), we 
suggest that differences in MSI profiles between endometrial and colorectal 
cancers reflect the duration of tumor development, with endometrial cancer 
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showing a relatively “young” tumor age and colorectal tumors developing over a 
longer period of time. 
In our investigation, TGFβRII and PTEN emerged as “target” genes for MSI 
in HNPCC colorectal and endometrial cancers, respectively.  The tumor 
suppressor effects of both are well established in both stable and unstable tumors 
(Markowitz et al. 1995; Grady et al. 1999; Mutter et al. 2000).  Additionally, MSI 
and HNPCC tumors show comparable frequencies of mutation of these genes 
(Myeroff et al. 1995; Kong et al. 1997; Fujiwara et al. 1998; Guanti et al. 2000; 
Percesepe et al. 2000; Cohn et al. 2000; Shin et al. 2001).  In accordance with our 
findings, Duval et al. (2002) also found tissue specific target gene mutations 
between colorectal cancers and endometrial cancers. 
Other studies have also focused on the issue of HNPCC tumor spectrum, 
among them are: Schulmann et al. (2005) who addressed small bowel carcinoma, 
Malander et al. (2005) who dealt with ovarian carcinoma, and Soravia et al. 
(2003) who proposed that prostate cancer be included in the spectrum.  Finally, a 
review by Watson and Riley (2005) predicts that the tumor spectrum of HNPCC 
may expand as even more studies are carried out.  
 
 
 52
6. CONCLUSIONS  
 
• Development of  MSI and MSS tumors is distinguished by different 
epigenetic phenotypes in colonic mucosa of individuals, possibly 
underlying the differential developmental pathways of the corresponding 
tumors.  
 
• Epigenetic modification, methylation, is a major mechanism of MLH1 
inactivation in sporadic MSI colorectal cancers.  Hereditary nonpolyposis 
colorectal cancer tumors with MLH1 germline mutations exhibit a 
significantly lower prevalence for MLH1 promoter hypermethylation, 
explaining some differences in clinicopathological characteristics and 
tumorigenic pathways between sporadic and hereditary MSI colorectal 
cancers. 
 
• Unlike colorectal cancer scenarios, a significant pathogenic role in both 
HNPCC and sporadic endometrial carcinogenesis is played by PTEN.  In 
HNPCC-related endometrial carcinomas, somatic PTEN mutation, 
especially frameshift, is a consequence of profound MMR deficiency, 
contrary to sporadic MSI endometrial cancers in which  PTEN mutations 
may precede MMR deficiency.   
 
• Important determinants of the HNPCC tumor spectrum may,  despite 
identical genetic predisposition for endometrial and colorectal cancers, be 
different instability profiles and organ-specific target genes.  
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7. FUTURE PROSPECTS  
 
7.1. COLORECTAL CARCINOMA (I-II) 
 
Most sporadic MSI tumors have  an MLH1-associated etiology influenced 
primarily by epigenetic modification causing MLH1 inactivation.  Clarification of 
the cause and mechanisms of such hypermethylation and of its tumorigenic 
targets, besides the MLH1 gene, as well as identification of the basis of MSI in 
the minority (20%) of sporadic MSI colorectal cancers not associated with 
decreased expression of the MSH2 or MLH1 proteins, should become clear with 
further studies.  
Since by scrutinizing only some genes and CpG sites, we found evidence of 
clear parallels between normal mucosa methylation and clinical and biochemical 
properties of tumors, future elemental analyses of additional genes and 
methylation sites should help illuminate whether such distinct epigenetic changes 
are present on a more global scale. 
 
7.2. ENDOMETRIAL CARCINOMA (III-IV) 
 
We found tumor-specific patterns of MSI and target gene involvement for 
colorectal and endometrial cancer in HNPCC.  Similar comparative studies of 
other tumors from MMR gene mutation carriers would be useful in offering a 
better understanding of factors influencing different organ susceptibility to cancer 
development.  Collectively, such findings may one day abet the design of suitable 
surveillance and prevention strategies in HNPCC. 
PTEN inactivation plays an important pathogenic role in both HNPCC-related 
endometrial cancers and sporadic tumors but the somatic PTEN mutational 
spectra and frequency differ between HNPCC-related endometrial cancers and 
sporadic MSI endometrial cancers.  Further studies may help to confirm whether 
frameshift somatic PTEN mutations are a later consequence of profound MMR 
deficiency in HNPCC-related endometrial cancers, and whether somatic PTEN 
mutation or possible epigenetic inactivation may be one of the earliest, if not the 
earliest, events preceding MMR deficiency in sporadic endometrial cancers.  
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